Small interfering RNA targeting of the survivin gene inhibits human tumor cell growth in vitro

Zhang,Zhaoxia; Wang,Tianyou; Liu,Ziqin; Tang,Suoqin; Yue,Mei; Feng,Shunqiao; Hu,Mengze; Xuan,Litian; Chen,Yanfei

doi:10.3892/etm.2017.4501

Small interfering RNA targeting of the survivin gene inhibits human tumor cell growth in vitro

Authors:
- Zhaoxia Zhang
- Tianyou Wang
- Ziqin Liu
- Suoqin Tang
- Mei Yue
- Shunqiao Feng
- Mengze Hu
- Litian Xuan
- Yanfei Chen
View Affiliations

Affiliations: Department of Hematology and Oncology, Capital Institute of Pediatrics, Beijing 100020, P.R. China, Department of Hematology and Oncology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, P.R. China, Department of Pediatrics, Capital Institute of Pediatrics, Beijing 100020, P.R. China, Department of Pediatrics, People's Liberation Army General Hospital, Beijing 100039, P.R. China
Published online on: May 23, 2017 https://doi.org/10.3892/etm.2017.4501
Pages: 35-42
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the impact of small interfering RNA (siRNA) targeting of the survivin gene in human tumor cells and the effect of decreased survivin expression on the proliferation and apoptosis of tumor cells. Human tumor cell lines (MSA‑MB‑231, SGC‑7901, HeLa, A549, SK‑OV‑3 and Raji, PC‑3) were cultured in vitro and divided into three groups: survivin siRNA‑treated, scrambled negative control siRNA‑treated and an untreated control group. The level of survivin mRNA and protein expression was subsequently determined by reverse transcription‑quantitative polymerase chain reaction and western blot analysis, respectively. Cell proliferation was also examined by an MTT assay following transfection and the apoptotic rate of cells was detected by Hoechst and Annexin V/propidium iodide staining. It was observed that relative to the control group, expression of survivin mRNA and protein in the survivin siRNA‑treated group was significantly downregulated. Furthermore, siRNA targeting of survivin lead to the inhibition of tumor cell proliferation, as well as an increase in their apoptotic rate in vitro. These data suggest that survivin may be a potential tumor biomarker and a novel target for the treatment of cancer.

View Figures

View References

1	Sydorak RM and Applebaum H: Soft Tissue TumorsFundamentals of Pediatric Surgery. Mattei P: Springer-Verlag; New York, NY: pp. 755–760. 2011, View Article : Google Scholar
2	Li W: The new concept of cancer supportive treatment. Electronic Journal of Metabolism and Nutrition of Cancer. 1:2014.
3	Horiot JC: At last-progress in the assessment of the adverse effects of cancer treatments. Lancet Oncol. 8:568–570. 2007. View Article : Google Scholar : PubMed/NCBI
4	Barrett PT, Petrides K, Eysenck SB and Eysenck HJ: The Eysenck personality questionnaire: An examination of the factorial similarity of PE, N and L across 34 countries. Personality Individual Differences. 25:805–819. 1998. View Article : Google Scholar
5	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
6	Zaffaroni N and Daidone MG: Survivin expression and resistance to anticancer treatments: Perspectives for new therapeutic interventions. Drug Resistance Updates. 5:65–72. 2002. View Article : Google Scholar : PubMed/NCBI
7	Kong LJ, Zhao J and Fan WW: Survivin and Tumor Angiogenesis. Zhong Liu Xue Za Zhi. 15:950–952. 2009.(In Chinese).
8	Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M, Akahane K and Shiraki K: Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16 (INK4a) and Cdk2/cyclin E complex activation. Oncogene. 19:3225–3234. 2000. View Article : Google Scholar : PubMed/NCBI
9	Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC and Altieri DC: Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol. 158:1757–1765. 2001. View Article : Google Scholar : PubMed/NCBI
10	Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
11	Kayaselcuk F, Nursal T, Polat A, Noyan T, Yildirim S, Tarim A and Seydaoglu G: Expresion of survivin, Bcl-2, P53 and bax in breast carcioma and ductal intraepithelial neoplasia (DIN 1a). J Exp Clin Cancer Res. 23:105–112. 2004.PubMed/NCBI
12	Ryan BM, O'Donovan N and Duffy MJ: Survivin: A new target for anti-cancer therapy. Cancer Treat Rev. 35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
13	Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 22:8581–8589. 2003. View Article : Google Scholar : PubMed/NCBI
14	Chen XQ, Yang S, Li ZY, Lu HS, Kang MQ and Lin TY: Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells. Mol Med Rep. 5:917–922. 2012.PubMed/NCBI
15	Baker B, Eldrup A, Manoharan M, et al: RNA-induced silencing complexes; RNA interference; gene expression inhibition US patent 10/700,884. October 4–2003, issued February 17. 2005
16	Aliabadi H Montazeri, Landry B, Mahdipoor P and Uludag H: Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line. Mol Pharm. 8:1821–1830. 2011. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Mirandola P, Sponzilli I, Gobbi G, Marmiroli S, Rinaldi L, Binazzi R, Piccari GG, Ramazzotti G, Gaboardi GC, Cocco L and Vitale M: Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins. Int J Oncol. 28:127–133. 2006.PubMed/NCBI
19	Stewart B and Wild C: World cancer report 2014. International Agency for Research on Cancer; Lyon: 2014
20	Organization WH: ES Fact sheet 310: Top causes of death. Centro De Prensa. 2014.
21	Arnold LD, Ji QS, Buck E, Haley JD and Mulvihill MJ: Combination cancer therapy U.S. Patent 8,575,164. 2013
22	Yang Y and Huang S: Discuss the strengths and weaknesses between tumour biotherapy and chemoradiotherapy. Medical Information. 24:3503–3504. 2011.
23	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
24	Reed JC: Dysregulation of apoptosis in cancer. J Clin Oncol. 17:2941–2953. 1999. View Article : Google Scholar : PubMed/NCBI
25	Chiou SK, Jones MK and Tarnawski AS: Survivin-an anti-apoptosis protein: Its biological roles and implications for cancer and beyond. Med Sci Monit. 9:PI25–PI29. 2003.PubMed/NCBI
26	Merritt WM, Bar-Eli M and Sood AK: The dicey role of Dicer: Implications for RNAi therapy. Cancer Res. 70:2571–2574. 2010. View Article : Google Scholar : PubMed/NCBI
27	Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, et al: Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 28:172–176. 2010. View Article : Google Scholar : PubMed/NCBI
28	Medarova Z, Pham W, Farrar C, Petkova V and Moore A: In vivo imaging of siRNA delivery and silencing in tumors. Nat Med. 13:372–377. 2007. View Article : Google Scholar : PubMed/NCBI
29	Wenying Z, Zhaoning J, Zhimin Y, Dongyun C and Lili S: Survivin siRNA inhibits gastric cancer in nude mice. Cell Biochem Biophys. 62:337–341. 2012. View Article : Google Scholar : PubMed/NCBI
30	Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R and Rödel C: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 65:4881–4887. 2005. View Article : Google Scholar : PubMed/NCBI
31	Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U, Taubert H, Wirth MP and Meye A: siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol. 25:1065–1071. 2004.PubMed/NCBI
32	Endoh A, Asanuma K, Moriai R, Yamada M, Koyanagi Y, Sato T, Yagihasi A, Nakamura M, Kobayashi D and Watanabe N: Expression of survivin mRNA in CD34-positive cells. Clin Chim Acta. 306:149–151. 2001. View Article : Google Scholar : PubMed/NCBI
33	Lee GH, Joo YE, Koh YS, Chung IJ, Park YK, Lee JH, Kim HS, Choi SK, Rew JS, Park CS and Kim SJ: Expression of survivin in gastric cancer and its relationship with tumor angiogenesis. Eur J Gastroenterol Hepatol. 18:957–963. 2006. View Article : Google Scholar : PubMed/NCBI
34	Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM and Altieri DC: Urine detection of survivin and diagnosis of bladder cancer. JAMA. 285:324–328. 2001. View Article : Google Scholar : PubMed/NCBI
35	Yao X, Liu F, Qi X, Wu B, Yin HL, Ma HH, Shi QL, Zhou XJ and Li JS: Expression of survivin in human gastric adenocarcinomas: Correlation with proliferation and apoptosis. Zhonghua Wai Ke Za Zhi. 42:145–148. 2004.(In Chinese). PubMed/NCBI